Acadia Pharmaceuticals | ACAD - Debt


Acadia Pharmaceuticals reported $52.19M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 6.11M 251K Dec/2025
Cytokinetics USD 1.29B 4.48M Mar/2026
Eisai JPY 236.67B 49.14B Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Incyte USD 39.43M 982K Mar/2026
J&J USD 47.93B 2.14B Dec/2025
Moderna USD 1.31B 571M Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Prothena USD 9.08M 699K Sep/2025
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026